Nutritional status of newly diagnosed paediatric patients with inflammatory bowel disease

2021 ◽  
Vol 46 ◽  
pp. S756
Author(s):  
D. Kofinova ◽  
R. Shentova ◽  
P. Hadzhiyski ◽  
H. Naydenov ◽  
P. Yaneva ◽  
...  
2021 ◽  
Vol 46 ◽  
pp. S757-S758
Author(s):  
D. Kofinova ◽  
R. Shentova ◽  
P. Hadzhiyski ◽  
H. Naydenov ◽  
P. Yaneva ◽  
...  

2019 ◽  
Vol 13 (10) ◽  
pp. 1287-1291 ◽  
Author(s):  
Hadar Moran-Lev ◽  
Tut Galai ◽  
Anat Yerushalmy-Feler ◽  
Yosef Weisman ◽  
Adi Anafy ◽  
...  

Abstract Background and Aims The role of hepcidin in inflammatory bowel disease [IBD] in children with anaemia is poorly understood. However, it has been shown that vitamin D suppresses hepcidin expression. We aimed to assess serum hepcidin levels and the effect of vitamin D treatment on those levels in newly diagnosed IBD paediatric patients. Methods Eighty-five children were prospectively recruited in the Dana-Dwek Children’s Hospital [40 newly diagnosed IBD, 45 healthy controls, 47% female, mean age 13.5 ± 3.4 years]. Blood samples for measurement of interleukin 6 [IL-6], C-reactive protein [CRP], hepcidin, iron parameters and 25-hydroxyvitamin D [25-(OH)-D] levels were obtained at baseline. Patients with mild-to-moderate signs and symptoms of IBD were treated with 4000 units of vitamin D daily for 2 weeks, after which the blood tests were repeated. Results Basal hepcidin, IL-6, CRP and platelet counts were significantly higher, and haemoglobin, serum iron and transferrin levels were significantly lower in the IBD children compared to controls [p < 0.001]. Eighteen patients completed 2 weeks of treatment with vitamin D. Following treatment, serum 25-(OH)-D concentrations increased by 40% [from 22.5 to 32.5 ng/mL], and serum hepcidin, CRP and ferritin levels decreased by 81%, 81% and 40% [from 33.9 to 6.7 ng/mL, from 23.9 to 4.7 mg/L, and from 27 to 16 ng/mL, respectively] [p ≤ 0.001]. Conclusion Serum hepcidin levels were significantly higher in IBD paediatric patients compared to controls. Following vitamin D treatment, serum hepcidin concentration decreased significantly. These findings suggest a potential role for vitamin D in treating anaemia in IBD children. ClinicalTrials.gov number NCT03145896


2020 ◽  
Vol 4 (1) ◽  
pp. e000786
Author(s):  
Abbie Maclean ◽  
James J Ashton ◽  
Vikki Garrick ◽  
R Mark Beattie ◽  
Richard Hansen

The assessment and management of patients with known, or suspected, paediatric inflammatory bowel disease (PIBD) has been hugely impacted by the COVID-19 pandemic. Although current evidence of the impact of COVID-19 infection in children with PIBD has provided a degree of reassurance, there continues to be the potential for significant secondary harm caused by the changes to normal working practices and reorganisation of services.Disruption to the normal running of diagnostic and assessment procedures, such as endoscopy, has resulted in the potential for secondary harm to patients including delayed diagnosis and delay in treatment. Difficult management decisions have been made in order to minimise COVID-19 risk for this patient group while avoiding harm. Initiating and continuing immunosuppressive and biological therapies in the absence of normal surveillance and diagnostic procedures have posed many challenges.Despite this, changes to working practices, including virtual clinic appointments, home faecal calprotectin testing kits and continued intensive support from clinical nurse specialists and other members of the multidisciplinary team, have resulted in patients still receiving a high standard of care, with those who require face-to-face intervention being highlighted.These changes have the potential to revolutionise the way in which patients receive routine care in the future, with the inclusion of telemedicine increasingly attractive for stable patients. There is also the need to use lessons learnt from this pandemic to plan for a possible second wave, or future pandemics as well as implementing some permanent changes to normal working practices.In this review, we describe the diagnosis, management and direct impact of COVID-19 in paediatric patients with IBD. We summarise the guidance and describe the implemented changes, evolving evidence and the implications of this virus on paediatric patients with IBD and working practices.


2013 ◽  
Vol 1 (4) ◽  
pp. 333-343 ◽  
Author(s):  
Michele Herzer Maddux ◽  
Julie A. Bass ◽  
Christy Geraghty-Sirridge ◽  
Ellen Carpenter ◽  
Kathy Christenson

2012 ◽  
Vol 57 (9) ◽  
pp. 2408-2415 ◽  
Author(s):  
Manie Juneja ◽  
Leonard Baidoo ◽  
Marc B. Schwartz ◽  
Arthur Barrie ◽  
Miguel Regueiro ◽  
...  

2001 ◽  
Vol 121 (2) ◽  
pp. 504-505 ◽  
Author(s):  
Asghar Qasim ◽  
John Seery ◽  
C.A.O. Morain

Sign in / Sign up

Export Citation Format

Share Document